1. Scrip
  2. >>New Products

With One Launch Under Way, SpringWorks Ramps Up For A Second

CEO Saqib Islam discussed the company’s growth strategy

 
• By Jessica Merrill

The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.

SpringWorks is preparing to launch a second drug. • Source: Shutterstock

SpringWorks Therapeutics Inc. launched its first rare disease drug late last year and is beginning the US regulatory review process for a second, with an eye toward reaching profitability in 2025 or 2026. The company is at an interesting inflection moment, emerging as a commercial-stage rare disease firm, CEO Saqib Islam said in an interview with Scrip.

Key Takeaways
  • The launch of Ogsiveo has gotten off to a strong start as the first treatment for adults with progressing desmoid tumors.
  • The company hopes to launch...

The US Food and Drug Administration approved its first drug, the gamma secretase inhibitor Ogsiveo (nirogacestat), in November last year as the first treatment for adults with progressing desmoid tumors....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

More from Scrip

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 
• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.